Trial Profile
A retrospective, single-centre study of Avibactam/ceftazidime for the treatment of Carbapenem-Resistant Enterobacteriaceae infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Enterobacteriaceae infections; Gram-negative infections
- Focus Adverse reactions; Therapeutic Use
- 12 May 2017 New trial record
- 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases